UF startup ViewRay Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market new soft tissue visualization capabilities for its MRIdian image-guided radiation therapy (IGRT) system.
The new upgradable capabilities enhance the features of MRIdian’s SmartVISION MRI (magnetic resonance imaging), including:
- Expanded high-definition visualization and enhanced contrast between different tissues, to assist clinicians with tissue visualization and beam contouring;
- The potential to aid in the assessment and prediction of tumor response to radiation therapy is enabled by “DWI”, a diffusion weighted imaging feature that tracks treatment progress by distinguishing between tumor and normal tissues;
- Faster, brighter, more detailed anatomical planar imaging to strike tumors with greater precision and accuracy through proprietary technology, which allows for a 2X increase in MRI speed (to 8 frames per second), a 2X increase in image resolution, and a 2X improvement in MR signal-to-noise ratio (SNR); and
- Potential reduction in treatment delivery time through enhanced multileaf collimator (MLC) speed.
